Celldex Therapeutics, Inc. (CLDX) Balance Sheet

The sequential decline in total assets, despite a $271M equity raise in 2026Q2, underscores that operating losses are outpacing capital infusions. The accumulated deficit growth of roughly $600M over ten quarters aligns with the escalating Phase 3 burn, suggesting the balance sheet is being depleted to fund clinical milestones. Investors should monitor whether future financings can offset the accelerating cash consumption.

Despite the current ratio of 11.82, the absolute cash position is minimal relative to the burn rate. The $47.5M cash balance, even after the recent equity raise, covers less than one quarter of operating expenses, which averaged over $60M in recent quarters. This suggests an imminent need for additional financing or a strategic partnership to sustain operations through the Phase 3 program.

The near-zero debt is typical for a clinical-stage biotech, but it also means there is no debt cushion to absorb operational shocks. The $4.9M debt is likely lease-related and immaterial. The absence of debt financing suggests that future capital needs will be met through equity dilution, which could pressure existing shareholders if the stock price weakens.

The balance sheet is dominated by cash and marketable securities, with PP&E representing less than 2% of total assets. Goodwill is stable at $27.2M, likely from an acquisition, but there is no impairment risk indicated. The lack of capitalized R&D means the most valuable assets—intellectual property and clinical data—are off-balance-sheet, making the book value understate the company's true potential.

The equity base is positive only because of frequent equity offerings; without them, the accumulated deficit would have rendered the company insolvent. The negative retained earnings highlight the magnitude of past R&D spending and the reliance on external capital. Future dilution is likely as the company continues to fund Phase 3 trials, which may further dilute existing shareholders.